II
EGRX

Inspire Investing’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Inspire Investing’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-958
Closed -$51K – 741
2017
Q4 		$51K Buy
+958
New +$53.3K 0.04% 734

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Inspire Investing's EGRX Position: Q1 2018 in Review

Inspire Investing sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2018, closing a stake of 958 shares — an estimated $51K sold.

Inspire Investing first reported a position in EGRX in Q4 2017 and held it in 1 quarter. The position peaked at $51K in Q4 2017. 174 funds tracked by Wall St. Rank hold EGRX as of Q1 2018.

  • Inspire Investing reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Inspire Investing sold 958 Eagle Pharmaceuticals, Inc. shares in Q1 2018, an estimated $51K.
  • Inspire Investing first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Inspire Investing's Eagle Pharmaceuticals, Inc. position peaked at $51K in Q4 2017.
  • 174 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2018.

Based on Inspire Investing's 13F filing for Q1 2018, filed 13 Apr 2018.